Kisunla™

Description

Kisunla™ (donanemab-azbt)

Kisunla™ is an advanced monoclonal antibody therapy designed to help slow cognitive decline in adults with early symptomatic Alzheimer’s disease.

Developed as a targeted amyloid plaque therapy, Kisunla works by helping the body remove abnormal amyloid-beta protein deposits in the brain — one of the key biological features associated with Alzheimer’s disease progression. (European Medicines Agency (EMA))

Key Benefits

• Helps slow memory and cognitive decline
• Targets amyloid plaques directly in the brain
• Designed for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease
• Administered as a once-monthly intravenous infusion
• Supports preservation of daily functioning and independence (Drugs.com)

How It Works

Kisunla contains donanemab-azbt, a monoclonal antibody that binds to amyloid-beta plaques in the brain. This activates the body’s immune response to help clear plaque buildup associated with Alzheimer’s disease progression. (European Medicines Agency (EMA))

Indication

Kisunla is indicated for:

• Adults with early symptomatic Alzheimer’s disease
• Patients with mild cognitive impairment (MCI) or mild dementia stage associated with Alzheimer’s disease (U.S. Food and Drug Administration)

Administration

• Given as an intravenous (IV) infusion every 4 weeks
• Administered under medical supervision
• Patients may require MRI monitoring during treatment to evaluate safety and treatment response (European Medicines Agency (EMA))

Why Choose Kisunla

Kisunla represents a new generation of Alzheimer’s treatment focused on targeting the underlying biology of disease progression rather than only managing symptoms. It offers a precision-based therapeutic approach for eligible patients in the early stages of Alzheimer’s disease.

Important Safety Information

Kisunla may cause serious side effects including amyloid-related imaging abnormalities (ARIA) such as brain swelling or bleeding. Treatment should only be managed by qualified healthcare professionals with appropriate monitoring. (Drugs.com)